We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
NUVO - Division of Medical Illumination

Download Mobile App





Same Day DNA Sequencing-Based Test Identifies Secondary Infections in COVID-19 Patients

By HospiMedica International staff writers
Posted on 23 Nov 2021
Print article
Illustration
Illustration

A same-day test has been shown to successfully identify secondary infections in COVID-19 patients in the intensive care unit (ICU) within hours rather than days.

The DNA sequencing-based test developed by researchers at Guy’s and St Thomas’ (London, UK) was evaluated by doctors in the ICU at St Thomas’ Hospital with 34 ICU patients during the first COVID-19 pandemic wave. The study showed how this rapid test will ensure patients get the right antibiotic faster, while also minimizing unnecessary antibiotic prescriptions to reduce the risk of antimicrobial resistance. The tests were evaluated for COVID-19 patients and shown to identify both bacterial and fungal infections and identify outbreaks with resistant bacteria within 24 hours. This is particularly important for COVID-19 patients who are highly susceptible to secondary infection and outbreaks.

When critically ill patients are cared for in the ICU, doctors take deep samples from their lungs. Currently, these samples are often sent to multiple labs where different bacterial and fungal cultures are set up alongside other complex molecular tests. Initial results take two to four days to return. During this time the patient often remains on standard antibiotic treatment, some of which may be unnecessary. In other patients, the treatment may be ineffective, as the bacteria has resistance genes to the standard antibiotics. The new same-day service uses cutting edge Nanopore sequencing technology to identify all bacterial and fungal pathogens present in patients’ samples, as well as any resistance genes present. The advance means that unnecessary treatment can be reduced, and patients can benefit from starting the right treatment sooner. The following day, the same test provides enough genetic sequence to compare pathogen genomes with a database that accurately identifies patients carrying the same strain so outbreaks can be detected at the very start. This is the first time this combined benefit of a single test has been demonstrated.

“As soon as the pandemic started, our scientists realized there would be a benefit to sequencing genomes of all bacteria and fungi causing infection in COVID-19 patients while on ICU,” said Professor Jonathan Edgeworth, Director of the Centre for Clinical Infection and Diagnostics Research (CIDR) and Medical Director of Viapath, who led the research. “Within a few weeks we showed it can diagnose secondary infection, target antibiotic treatment and detect outbreaks much earlier than current technologies – all from a single sample. This will revolutionize our approach to prevention and treatment of serious infection on ICU and we now plan to offer it as a clinical service for COVID-19 and influenza patients this coming winter.”

Related Links:
Guy’s and St Thomas’ 

Gold Supplier
Portable X-Ray System
FDR Xair
New
Silver Supplier
Patient Simulator
PatSim 200
New
Oxygen Therapy Hyperbaric Chamber
Sechrist 2800
New
Electric Gynecological Operating Table
YF-6

Print article
FIME - Informa

Channels

AI

view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Critical Care

view channel
Image: The novel intravascular, catheter-based technology is designed to treat pulmonary hypertension (Photo courtesy of Freepik)

Minimally Invasive Catheter-Based Technology Treats Pulmonary Hypertension

Pulmonary hypertension, a deadly condition impacting roughly 500,000 patients annually across the world, is currently categorized as a rare disease. As it stands, available treatment options are restricted,... Read more

Surgical Techniques

view channel
Image: LIBERTY is the first ever single-use endovascular surgical robotic system designed to streamline endovascular procedures (Photo courtesy of Microbot Medical)

Tiny Surgical Robot Designed to Streamline Endovascular Interventional Procedures

The endovascular field currently has several unmet needs that can be fulfilled with robotics. However, the current uptake of robotics in this sector is exceptionally low, largely due to several barriers... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: VCM viscoelastic testing instrument provides rapid, real-time hemostasis assessment at POC (Photo courtesy of Entegrion)

Next Gen Viscoelastic Coagulation Monitor Enables Rapid Hemostasis Assessment at Patient Side

The use of viscoelastic coagulation testing is on the rise for various applications such as trauma, surgery, obstetrics, major disease management, and more. It provides crucial information not obtained... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.